What is the share price of Novelix Pharmaceuticals Ltd (NOVELIX) today?
The share price of NOVELIX as on 2nd June 2025 is ₹27.94. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Novelix Pharmaceuticals Ltd (NOVELIX) share?
The past returns of Novelix Pharmaceuticals Ltd (NOVELIX) share are- Past 1 week: N/A%
- Past 1 month: 5.00%
- Past 3 months: 10.22%
- Past 6 months: 21.48%
- Past 1 year: 54.88%
- Past 3 years: 203.04%
- Past 5 years: 1311.11%
What are the peers or stocks similar to Novelix Pharmaceuticals Ltd (NOVELIX)?
The peers or stocks similar to Novelix Pharmaceuticals Ltd (NOVELIX) include:What is the market cap of Novelix Pharmaceuticals Ltd (NOVELIX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Novelix Pharmaceuticals Ltd (NOVELIX) is ₹27.80 Cr as of 2nd June 2025.What is the 52 week high and low of Novelix Pharmaceuticals Ltd (NOVELIX) share?
The 52-week high of Novelix Pharmaceuticals Ltd (NOVELIX) is ₹27.94 and the 52-week low is ₹18.04.Which sector does Novelix Pharmaceuticals Ltd (NOVELIX) belong to?
Novelix Pharmaceuticals Ltd (NOVELIX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Novelix Pharmaceuticals Ltd (NOVELIX) shares?
You can directly buy Novelix Pharmaceuticals Ltd (NOVELIX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Novelix Pharmaceuticals Ltd
NOVELIX Share Price
27.940.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NOVELIX Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
NOVELIX Performance & Key Metrics
NOVELIX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 252.73 | — | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.63 | 6.56 | 0.84% |
NOVELIX Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NOVELIX Company Profile
Novelix Pharmaceuticals Ltd engages in trading pharmaceuticals and related products, alongside investments in shares and securities.
SUNPHARMA
PE Ratio
36.86
36.86
1Y Return
14.02%
14.02%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.04
23.04
1Y Return
0.87%
0.87%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.44
19.44
1Y Return
12.11%
12.11%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
55.86
55.86
1Y Return
13.38%
13.38%
Buy Reco %
72.00
72.00
MANKIND
PE Ratio
48.76
48.76
1Y Return
9.09%
9.09%
Buy Reco %
81.25
81.25
NOVELIX Forecast
NOVELIX Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NOVELIX
NOVELIX
Income
Balance Sheet
Cash Flow
Annual Normal View
NOVELIX Income Statement
NOVELIX Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.65 | 3.12 | 3.72 | 1.50 | 1.31 | 1.39 | 1.92 | 4.53 | 30.73 | 30.73 | ||||||||||
Raw Materials | 3.07 | 1.99 | 2.77 | 0.73 | 0.88 | 1.09 | 1.64 | 4.21 | 30.57 | 30.58 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | ||||||||||||
| Employee Cost | 0.00 | 0.13 | 0.18 | 0.13 | 0.15 | 0.14 | 0.16 | 0.13 | ||||||||||||
| Selling & Administrative Expenses | 0.48 | 0.33 | 0.42 | 0.35 | 0.31 | 0.38 | 0.36 | 0.34 | ||||||||||||
| Operating & Other expenses | -0.22 | 0.24 | 0.04 | 0.08 | 3.15 | 1.27 | -0.25 | -0.20 | ||||||||||||
EBITDA | 0.32 | 0.43 | 0.31 | 0.19 | -3.19 | -1.50 | -0.00 | 0.05 | 0.16 | 0.15 | ||||||||||
| Depreciation/Amortization | 0.12 | 0.15 | 0.12 | 0.08 | 0.08 | 0.07 | 0.06 | 0.04 | 0.04 | 0.02 | ||||||||||
| PBIT | 0.20 | 0.28 | 0.19 | 0.11 | -3.27 | -1.57 | -0.06 | 0.01 | 0.12 | 0.13 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | 0.20 | 0.28 | 0.19 | 0.11 | -3.27 | -1.57 | -0.06 | 0.01 | 0.12 | 0.13 | ||||||||||
| Taxes & Other Items | 0.05 | 0.10 | -0.06 | 0.02 | 0.00 | -0.01 | 0.00 | 0.01 | 0.04 | 0.02 | ||||||||||
| Net Income | 0.15 | 0.18 | 0.25 | 0.09 | -3.27 | -1.56 | -0.06 | 0.00 | 0.08 | 0.11 | ||||||||||
| EPS | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.00 | 0.09 | 0.14 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NOVELIX Company Updates
NOVELIX Stock Peers
NOVELIX Past Performance & Peer Comparison
NOVELIX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Novelix Pharmaceuticals Ltd | 347.50 | — | — |
| Sun Pharmaceutical Industries Ltd | 36.86 | 6.00 | 0.95% |
| Cipla Ltd | 23.04 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 19.44 | 3.89 | 0.61% |
NOVELIX Stock Price Comparison
Compare NOVELIX with any stock or ETFCompare NOVELIX with any stock or ETF
NOVELIX
NOVELIX Holdings
NOVELIX Shareholdings
NOVELIX Promoter Holdings Trend
NOVELIX Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NOVELIX Institutional Holdings Trend
NOVELIX Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NOVELIX Shareholding Pattern
NOVELIX Shareholding Pattern
NOVELIX Shareholding History
NOVELIX Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NOVELIX stock
smallcases containing NOVELIX stock
Looks like this stock is not in any smallcase yet.
NOVELIX Events
NOVELIX Events
NOVELIX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NOVELIX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NOVELIX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NOVELIX has not given any dividends in last 5 years
NOVELIX Upcoming Dividends
NOVELIX Upcoming Dividends
No upcoming dividends are available
NOVELIX Past Dividends
NOVELIX Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2012
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Aug 16, 2012
Cash Dividend
Ex DateEx DateSep 22, 2011
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2011
NOVELIX Stock News & Opinions
NOVELIX Stock News & Opinions
Articles & Videos
Earnings
Novelix Pharmaceuticals standalone net profit declines 35.71% in the March 2025 quarter
Net profit of Novelix Pharmaceuticals declined 35.71% to Rs 0.18 crore in the quarter ended March 2025 as against Rs 0.28 crore during the previous quarter ended March 2024. Sales rose 2383.33% to Rs 20.86 crore in the quarter ended March 2025 as against Rs 0.84 crore during the previous quarter ended March 2024. For the full year,net profit rose 700.00% to Rs 0.08 crore in the year ended March 2025 as against Rs 0.01 crore during the previous year ended March 2024. Sales rose 627.96% to Rs 30.72 crore in the year ended March 2025 as against Rs 4.22 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales20.860.84 2383 30.724.22 628 OPM %1.1019.05 -0.46-5.92 - PBDT0.230.29 -21 0.160.06 167 PBT0.210.28 -25 0.120.02 500 NP0.180.28 -36 0.080.01 700 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Novelix Pharmaceuticals to convene board meeting
Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Novelix Pharmaceuticals to convene EGM
Novelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Novelix Pharmaceuticals to convene board meeting
Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 April 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Trimurthi reports standalone net profit of Rs 0.15 crore in the December 2024 quarter
Net profit of Trimurthi reported to Rs 0.15 crore in the quarter ended December 2024 as against net loss of Rs 0.03 crore during the previous quarter ended December 2023. Sales rose 960.00% to Rs 5.30 crore in the quarter ended December 2024 as against Rs 0.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales5.300.50 960 OPM %2.45-22.00 - PBDT0.13-0.02 LP PBT0.13-0.03 LP NP0.15-0.03 LP Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Trimurthi to table results
Trimurthi will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Trimurthi to announce Quarterly Result
Trimurthi will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Trimurthi revises board meeting date
Trimurthi has revised the meeting of the Board of Directors which was scheduled to be held on 14 October 2024. The meeting will now be held on 21 October 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Trimurthi to hold board meeting
Trimurthi will hold a meeting of the Board of Directors of the Company on 14 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Trimurthi schedules AGM
Trimurthi announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.02%, vs industry avg of 9.02%
Over the last 5 years, market share stayed at 0%
Over the last 5 years, net income has grown at a yearly rate of -99.88%, vs industry avg of 15.28%